Copyright
        ©The Author(s) 2003.
    
    
        World J Gastroenterol. Jul 15, 2003; 9(7): 1385-1389
Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1385
Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1385
            Table 1 Classification of diverticular diseases of the colon
        
    | Clinical classification (modified from ref. 5) | 
| · Symptomatic uncomplicated disease | 
| · Recurrent symptomatic disease | 
| · Complicated disease (haemorrhage, abscess, phlegmon, perforation, purulent and faecal peritonitis, stricture, fistula, small-bowel obstruction due to post-inflammatory adhesions) | 
| Modified Hinchey classification (modified from refs. 41, 71) | 
| · Stage I: pericolic abscess | 
| · Stage IIa: distant abscess amenable to percutaneous drainage | 
| · Stage IIb: complex abscess associated with/without fistula | 
| · Stage III: generalized purulent peritonitis | 
| · Stage IV: faecal peritonitis | 
            Table 2 Effects of rifaximin (R) administration on symptoms in patients with diverticular disease
        
    | First author (year, ref) | Pts (n) | Treatment (type) | Duration (months) | Reduction in symptoms(%) | P | 
| Papi (1992, 64) | 217 | R (400 mg daily) + glucomannan (2 g daily) vs glucomannan | 12 | 63.9 vs 47.6 | < 0.001 | 
| Papi (1995, 65) | 168 | R (400 mg daily) + glucomannan (2 g daily) vs placebo +glucomannan | 12 | 68.9 vs 38.5 | < 0.001 | 
| Latella (2003, 66) | 968 | R (400 mg daily) + glucomannan (4 g daily) vs glucomannan | 12 | 56.5 vs 29.2 | < 0.001 | 
- Citation: Colecchia A, Sandri L, Capodicasa S, Vestito A, Mazzella G, Staniscia T, Roda E, Festi D. Diverticular disease of the colon: New perspectives in symptom development and treatment. World J Gastroenterol 2003; 9(7): 1385-1389
- URL: https://www.wjgnet.com/1007-9327/full/v9/i7/1385.htm
- DOI: https://dx.doi.org/10.3748/wjg.v9.i7.1385

 
         
                         
                 
                 
                 
                 
         
                         
                         
                        